ENDO-205 — the first peptide designed to remove endometriosis lesions, not just quiet them

ENDO-205 is interesting precisely because it starts from that gap. It is the lead program of a company called EndoCyclic Therapeutics, and it is described as a first-in-class, non-hormonal, targeted peptide therapeutic — a drug designed not to lower estrogen system-wide but to find endometriotic lesions and remove them. In March 2026 the FDA cleared its Investigational New Drug application, the regulatory step that allows human testing to begin, and the company said it planned to open a Phase 1 study in healthy, reproductive-age women. That is the honest frame for everything that follows: ENDO-205 is investigational. It is not approved, it is not available, and as of this writing its first human trial had not yet reported. What makes it worth understanding now is the idea behind it.

The idea is lesion selectivity. The company's platform produces small engineered peptides that are cell-permeating and pH-sensitive — built to behave differently inside diseased tissue than inside healthy tissue. In the case of ENDO-205, the peptide is designed to be taken up preferentially by endometriotic cells, and once inside, to trigger apoptosis: the cell's own programmed self-destruction pathway. Apoptosis is the orderly route a cell takes when it is meant to die — it condenses, packages itself, and is cleared without spilling its contents and inflaming the neighborhood. The intent, as described, is that the lesion's cells are pushed into that pathway and the body's immune system then clears the debris, removing the implant rather than merely starving it of hormonal signal. The non-hormonal part matters here: the design explicitly aims to avoid hormonal manipulation, broad immune suppression, and systemic toxicity, concentrating the action where the disease is.

It is worth pausing on how different that is from the conventional model, because the contrast is the whole point. Hormonal therapy works at the level of the body's estrogen economy — turn the supply down, and proliferation slows. But endometriotic lesions are notoriously self-sustaining; they make their own estrogen locally, run several reinforcing inflammatory and fibrotic circuits, and persist beneath whatever systemic suppression is achieved. A drug that lowers estrogen is working upstream of a tissue that has partly opted out of needing the body's estrogen at all. A drug that instead instructs the lesion's cells to die is working at the lesion. If that distinction holds up in people, it is the difference between managing a disease and modifying it — and "disease-modifying" is the language the field has started using about this candidate, carefully, because it has not yet been earned in a trial.

The preclinical picture is what justified the move into humans. In its IND-stage work the company reported that ENDO-205 eliminated endometriosis lesions and reduced the associated inflammation in animal models, and that GLP toxicology studies — the formal safety work the FDA requires before human dosing — showed no safety signals. That is a genuinely encouraging preclinical profile, and it is also exactly the point at which restraint is required. Preclinical lesion elimination is a reason to run a trial, not a result that transfers to women. The history of drug development is full of compounds that cleared animals and toxicology cleanly and then underperformed or surprised in people; the entire purpose of Phase 1, and the phases after it, is to find out which kind ENDO-205 is. The planned first study is in healthy reproductive-age volunteers, which is a safety-and-tolerability step, not an efficacy readout. Evidence that it shrinks or clears lesions in patients, and does so safely and durably, is several years and several trials away even in the best case.

There is also a wider significance to the program that is easy to miss in the mechanism. Endometriosis affects roughly one in ten women of reproductive age — on the order of 190 million worldwide — and it remains one of the most under-served conditions in medicine, with an average diagnostic delay measured not in months but in years. A field that has gone decades without a fundamentally new mechanism does not get a non-hormonal, lesion-targeting candidate into the clinic very often, and the arrival of one is meaningful regardless of how this particular molecule performs, because it signals that the lesion itself is becoming a tractable drug target. EndoCyclic has also described a companion program, an investigational imaging agent intended to detect endometriosis — including superficial lesions — without surgery, which speaks to the same ambition of treating the disease as something to find and act on directly rather than infer and suppress.

For anyone living with endometriosis right now, the practical takeaway is narrow and important: ENDO-205 is not something to ask for, because it does not yet exist as a treatment. The decisions that matter today — whether to pursue excision, which hormonal or non-hormonal strategy fits, how to address pain and fertility — are still made with the tools that are actually available, in conversation with a prescribing provider who knows your disease. What ENDO-205 offers is not an option but a direction. It is one of the clearest signs yet that the long-standing logic of endometriosis care — cut out what you can see, suppress the estrogen that feeds the rest — may eventually be joined by a third approach that goes after the lesion on its own terms. Whether ENDO-205 specifically becomes that treatment is now a question for the clinic to answer, and for the first time in a long time, the question is being asked at the level where the disease actually lives.